Kremer, J. M.; Bloom, B. J.; Breedveld, F. C.; Coombs, J. H.; Fletcher, M. P.; Gruben, D.; Krishnaswami, S.; Burgos-Vargas, R. N.; Wilkinson, B.; Zerbini, C. A. F.; Zwillich, S. H. (2009). «The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo». Arthritis & Rheumatism60 (7): 1895-1905. PMID19565475. doi:10.1002/art.24567.
Ken Garber (9 de enero de 2013). «Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market». Nature Biotechnology31 (1): 3-4. PMID23302910. doi:10.1038/nbt0113-3.
Papp KA, Menter MA, Abe M, et al. for the OPT Pivotal 1 and OPT Pivotal 2 Investigators. (7 de julio de 2015). «Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials.». Br J Dermatol. PMID26149717. doi:10.1111/bjd.14018.
Bachelez H, van de Kerkhof PC, Strohal R, et al. for the OPT Compare Investigators. (Aug 8, 2015). «Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.». Lancet.386 (9993): 552-61. PMID26051365. doi:10.1016/S0140-6736(14)62113-9.
Levy LL, Urban J, King BA (2015). «Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate». Journal of the American Academy of Dermatology73 (3): 395-399. PMID26194706. doi:10.1016/j.jaad.2015.06.045.
Kremer, J. M.; Bloom, B. J.; Breedveld, F. C.; Coombs, J. H.; Fletcher, M. P.; Gruben, D.; Krishnaswami, S.; Burgos-Vargas, R. N.; Wilkinson, B.; Zerbini, C. A. F.; Zwillich, S. H. (2009). «The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo». Arthritis & Rheumatism60 (7): 1895-1905. PMID19565475. doi:10.1002/art.24567.
Ken Garber (9 de enero de 2013). «Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market». Nature Biotechnology31 (1): 3-4. PMID23302910. doi:10.1038/nbt0113-3.
Papp KA, Menter MA, Abe M, et al. for the OPT Pivotal 1 and OPT Pivotal 2 Investigators. (7 de julio de 2015). «Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials.». Br J Dermatol. PMID26149717. doi:10.1111/bjd.14018.
Bachelez H, van de Kerkhof PC, Strohal R, et al. for the OPT Compare Investigators. (Aug 8, 2015). «Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.». Lancet.386 (9993): 552-61. PMID26051365. doi:10.1016/S0140-6736(14)62113-9.
Levy LL, Urban J, King BA (2015). «Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate». Journal of the American Academy of Dermatology73 (3): 395-399. PMID26194706. doi:10.1016/j.jaad.2015.06.045.
